Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2008 3
2009 4
2010 1
2011 5
2012 7
2013 6
2014 3
2015 4
2016 6
2017 7
2018 9
2019 6
2020 3
Text availability
Article attribute
Article type
Publication date

Search Results

52 results
Results by year
Filters applied: . Clear all
Page 1
Potential Therapeutic Effects of Psilocybin.
Johnson MW, Griffiths RR. Johnson MW, et al. Neurotherapeutics. 2017 Jul;14(3):734-740. doi: 10.1007/s13311-017-0542-y. Neurotherapeutics. 2017. PMID: 28585222 Free PMC article. Review.
Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial.
Griffiths RR, Johnson MW, Carducci MA, Umbricht A, Richards WA, Richards BD, Cosimano MP, Klinedinst MA. Griffiths RR, et al. J Psychopharmacol. 2016 Dec;30(12):1181-1197. doi: 10.1177/0269881116675513. J Psychopharmacol. 2016. PMID: 27909165 Free PMC article. Clinical Trial.
Classic psychedelics: An integrative review of epidemiology, therapeutics, mystical experience, and brain network function.
Johnson MW, Hendricks PS, Barrett FS, Griffiths RR. Johnson MW, et al. Pharmacol Ther. 2019 May;197:83-102. doi: 10.1016/j.pharmthera.2018.11.010. Epub 2018 Dec 4. Pharmacol Ther. 2019. PMID: 30521880 Review.
Long-term follow-up of psilocybin-facilitated smoking cessation.
Johnson MW, Garcia-Romeu A, Griffiths RR. Johnson MW, et al. Am J Drug Alcohol Abuse. 2017 Jan;43(1):55-60. doi: 10.3109/00952990.2016.1170135. Epub 2016 Jul 21. Am J Drug Alcohol Abuse. 2017. PMID: 27441452 Free PMC article. Clinical Trial.
The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act.
Johnson MW, Griffiths RR, Hendricks PS, Henningfield JE. Johnson MW, et al. Neuropharmacology. 2018 Nov;142:143-166. doi: 10.1016/j.neuropharm.2018.05.012. Epub 2018 Jun 5. Neuropharmacology. 2018. PMID: 29753748 Free PMC article. Review.
Classic Hallucinogens and Mystical Experiences: Phenomenology and Neural Correlates.
Barrett FS, Griffiths RR. Barrett FS, et al. Curr Top Behav Neurosci. 2018;36:393-430. doi: 10.1007/7854_2017_474. Curr Top Behav Neurosci. 2018. PMID: 28401522 Free PMC article. Review.
Psychedelic therapy for smoking cessation: Qualitative analysis of participant accounts.
Noorani T, Garcia-Romeu A, Swift TC, Griffiths RR, Johnson MW. Noorani T, et al. J Psychopharmacol. 2018 Jul;32(7):756-769. doi: 10.1177/0269881118780612. Epub 2018 Jun 25. J Psychopharmacol. 2018. PMID: 29938565
Double-blind comparison of the two hallucinogens psilocybin and dextromethorphan: effects on cognition.
Barrett FS, Carbonaro TM, Hurwitz E, Johnson MW, Griffiths RR. Barrett FS, et al. Psychopharmacology (Berl). 2018 Oct;235(10):2915-2927. doi: 10.1007/s00213-018-4981-x. Epub 2018 Jul 30. Psychopharmacology (Berl). 2018. PMID: 30062577 Free PMC article. Clinical Trial.
Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction.
Johnson MW, Garcia-Romeu A, Cosimano MP, Griffiths RR. Johnson MW, et al. J Psychopharmacol. 2014 Nov;28(11):983-92. doi: 10.1177/0269881114548296. Epub 2014 Sep 11. J Psychopharmacol. 2014. PMID: 25213996 Free PMC article. Clinical Trial.
Psilocybin-occasioned mystical-type experience in combination with meditation and other spiritual practices produces enduring positive changes in psychological functioning and in trait measures of prosocial attitudes and behaviors.
Griffiths RR, Johnson MW, Richards WA, Richards BD, Jesse R, MacLean KA, Barrett FS, Cosimano MP, Klinedinst MA. Griffiths RR, et al. J Psychopharmacol. 2018 Jan;32(1):49-69. doi: 10.1177/0269881117731279. Epub 2017 Oct 11. J Psychopharmacol. 2018. PMID: 29020861 Free PMC article. Clinical Trial.
52 results
Jump to page
Feedback